Abbott shares rise as investors refocus on diabetes tech and cancer-diagnostics momentum

Abbott Laboratories (ABT) is up 4.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to renewed optimism around Abbott’s product-news flow in diabetes care and oncology diagnostics, following recent regulatory and clinical-data updates. With the company also integrating its newly acquired cancer diagnostics business, traders may be positioning for improving growth sentiment after a volatile stretch.

Details:

Abbott announced a European CE Mark for a dual glucose-and-ketone sensing technology, a milestone that could expand its continuous monitoring platform into higher-acuity diabetes management use cases.

The company highlighted new clinical evidence across its cancer diagnostics portfolio presented around a major oncology conference, including data related to multi-cancer early detection and colorectal cancer screening.

A recent colorectal cancer screening guideline update emphasized broader screening options (including at-home stool testing and in-office blood-based testing), a backdrop that may be viewed as supportive for established noninvasive screening products in Abbott’s cancer diagnostics portfolio.

In recent SEC filings, Abbott disclosed that its acquisition of Exact Sciences closed on March 23, 2026, sharpening investor focus on the growth contribution from cancer diagnostics in 2026.

Sources:

Abbott, U.S. SEC, MedTech Dive, American Cancer Society

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ABT Insider Trading Activity

$ABT insiders have traded $ABT stock on the open market 11 times in the past 6 months. Of those trades, 5 have been purchases and 6 have been sales.

Here’s a breakdown of recent trading of $ABT stock by insiders over the last 6 months:

ROBERT B FORD (CHAIRMAN AND CEO) purchased 18,800 shares for an estimated $2,013,966
DANIEL J STARKS has made 3 purchases buying 20,000 shares for an estimated $2,013,868 and 0 sales.
PHILIP P BOUDREAU (EVP AND CFO) purchased 2,200 shares for an estimated $201,300
LOUIS H. MORRONE (EXECUTIVE VICE PRESIDENT) sold 1,144 shares for an estimated $132,223
DANIEL GESUA SIVE SALVADORI (EVP AND GROUP PRESIDENT) sold 885 shares for an estimated $102,288
ERIC SHROFF (Senior Vice President) sold 709 shares for an estimated $81,946
MARY K MORELAND (EXECUTIVE VICE PRESIDENT) sold 613 shares for an estimated $70,850
JOHN A. JR. MCCOY (VICE PRESIDENT AND CONTROLLER) sold 585 shares for an estimated $67,614
ELIZABETH C. CUSHMAN (EVP, GC AND SECRETARY) sold 263 shares for an estimated $30,397

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$ABT Hedge Fund Activity

We have seen 1,249 institutional investors add shares of $ABT stock to their portfolio, and 1,883 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

J. STERN & CO. LLP removed 39,003,051 shares (-99.2%) from their portfolio in Q1 2026, for an estimated $3,959,199,707
CHARLES SCHWAB INVESTMENT MANAGEMENT INC added 32,310,527 shares (+245.0%) to their portfolio in Q1 2026, for an estimated $3,279,841,595
CAPITAL INTERNATIONAL INVESTORS removed 25,731,218 shares (-40.7%) from their portfolio in Q1 2026, for an estimated $2,611,975,939
FISHER ASSET MANAGEMENT, LLC removed 10,688,150 shares (-93.4%) from their portfolio in Q1 2026, for an estimated $1,084,954,106
CAPITAL RESEARCH GLOBAL INVESTORS added 10,606,123 shares (+27.1%) to their portfolio in Q1 2026, for an estimated $1,076,627,545
FRANKLIN RESOURCES INC added 8,867,817 shares (+79.5%) to their portfolio in Q1 2026, for an estimated $900,172,103
CAPITAL WORLD INVESTORS removed 8,466,861 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $859,471,060

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ABT Government Contracts

We have seen $124,867,450 of award payments to $ABT over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

VISN1 BPA FOR IMMUNOCHEMISTRY CPRR TESTING ADDING EQUIPMENT FOR MANCHESTER NH VAMC - WITHIN ORIGINAL SCOPE: $4,335,000
CHEMISTRY IMMUNOASSAY ANALYZER COST PER REPORTABLE RESULT (CPRR) PRICE SCHEDULE UPDATE: $4,000,483
LAB CHEMISTRY SERVICES: $3,620,964
CIVILIAN DRUG FREE WORKPLACE COLLECTIONS AND MEDICAL REVIEW SUPPORT SERVICES.: $3,510,144
CHEMISTRY ANALYZERS.: $2,801,823

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$ABT Congressional Stock Trading

Members of Congress have traded $ABT stock 9 times in the past 6 months. Of those trades, 2 have been purchases and 7 have been sales.

Here’s a breakdown of recent trading of $ABT stock by members of Congress over the last 6 months:

REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 05/27.
REPRESENTATIVE RICHARD MCCORMICK purchased up to $15,000 on 03/19.
REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 02/10, 12/19.
REPRESENTATIVE THOMAS H. KEAN, JR. purchased up to $15,000 on 01/29.
REPRESENTATIVE JULIE JOHNSON sold up to $15,000 on 12/18.
REPRESENTATIVE JULIA LETLOW sold up to $15,000 on 12/08.
REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 12/04.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$ABT Analyst Ratings

Wall Street analysts have issued reports on $ABT in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Barclays issued a "Overweight" rating on 02/02/2026
BTIG issued a "Buy" rating on 01/23/2026

To track analyst ratings and price targets for $ABT, check out Quiver Quantitative's $ABT forecast page.

$ABT Price Targets

Multiple analysts have issued price targets for $ABT recently. We have seen 12 analysts offer price targets for $ABT in the last 6 months, with a median target of $120.5.

Here are some recent targets:

Marie Thibault from BTIG set a target price of $131.0 on 04/27/2026
Matt Miksic from Barclays set a target price of $143.0 on 04/20/2026
Adam Maeder from Piper Sandler set a target price of $115.0 on 04/17/2026
Suraj Kalia from Oppenheimer set a target price of $115.0 on 04/17/2026
Vijay Kumar from Evercore ISI Group set a target price of $120.0 on 04/17/2026
Bruce D. Jackson from Benchmark set a target price of $120.0 on 04/17/2026
Shagun Singh from RBC Capital set a target price of $130.0 on 04/17/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.